Abrupt increase of tacrolimus blood levels during an episode of Shigella infection in a child after liver transplantation

被引:11
作者
Zylber-Katz, E
Granot, E
机构
[1] Hebrew Univ Jerusalem, Hadassah Univ Hosp, Hadassah Med Sch, Dept Pediat, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Hadassah Univ Hosp, Hadassah Med Sch, Clin Pharmacol Serv, IL-91120 Jerusalem, Israel
关键词
liver transplant; tacrolimus; Shigella; diarrhea;
D O I
10.1097/00007691-200112000-00009
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The authors report the case of an 8-year-old girl who underwent a liver transplant at the age of 18 months because of biliary atresia. She was treated with cyclosporin for more than 5 years. Increased hirsutism prompted a change to tacrolimus therapy. During 11 months the mean tacrolimus level was 8.2 ng/mL. The patient was hospitalized because of an episode of Shigella infection and a threefold increase in tacrolimus level was measured. Despite a reduction of tacrolimus dose, the trough tacrolimus levels were in the range of 16.5 to 22.0 ng/mL during the subsequent 2 weeks. On resolution of the diarrhea, tacrolimus levels returned to those observed before the Shigella infection. It is suggested that the marked increase in tacrolimus levels observed in this patient is a direct result of the damage produced to the gastrointestinal mucosa by the Shigella infection.
引用
收藏
页码:647 / 649
页数:3
相关论文
共 11 条
[1]   Tacrolimus (FK-506) treatment of fulminant colitis in a child [J].
Bousvaros, A ;
Wang, A ;
Leichtner, AM .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1996, 23 (03) :329-333
[2]  
Eades S K, 2000, Pediatr Transplant, V4, P63, DOI 10.1034/j.1399-3046.2000.00086.x
[3]   Tacrolimus oral bioavailability doubles with coadministration of ketoconazole [J].
Floren, LC ;
Bekersky, I ;
Benet, LZ ;
Mekki, Q ;
Dressler, D ;
Lee, JW ;
Roberts, JP ;
Hebert, MF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (01) :41-49
[4]   ORAL ABSORPTION OF FK506 IN RATS [J].
KAGAYAMA, A ;
TANIMOTO, S ;
FUJISAKI, J ;
KAIBARA, A ;
OHARA, K ;
IWASAKI, K ;
HIRANO, Y ;
HATA, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (10) :1446-1450
[5]  
Matsui A, 1996, ACTA PAEDIATR JAPON, V38, P699
[6]   DIFFERENCES IN ORAL FK506 DOSE REQUIREMENTS BETWEEN ADULT AND PEDIATRIC LIVER-TRANSPLANT PATIENTS [J].
MCDIARMID, SV ;
COLONNA, JO ;
SHAKED, A ;
VARGAS, J ;
AMENT, ME ;
BUSUTTIL, RW .
TRANSPLANTATION, 1993, 55 (06) :1328-1332
[7]  
MEKKI Q, 1993, CLIN PHARMACOL THER, V53, P229
[8]   TACROLIMUS - A REVIEW OF ITS PHARMACOLOGY, AND THERAPEUTIC POTENTIAL IN HEPATIC AND RENAL-TRANSPLANTATION [J].
PETERS, DH ;
FITTON, A ;
PLOSKER, GL ;
FAULDS, D .
DRUGS, 1993, 46 (04) :746-794
[9]  
Sansonetti P, 2000, PRESSE MED, V29, P2040
[10]   CELLULAR-LOCALIZATION OF THE MULTIDRUG-RESISTANCE GENE-PRODUCT P-GLYCOPROTEIN IN NORMAL HUMAN-TISSUES [J].
THIEBAUT, F ;
TSURUO, T ;
HAMADA, H ;
GOTTESMAN, MM ;
PASTAN, I ;
WILLINGHAM, MC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) :7735-7738